Elderly patients have often been excluded from, or under represented in, clinical trials. Now, a phase III trial has demonstrated that a platinum-based doublet regimen provides superior outcomes in elderly patients with advanced-stage non-small-cell lung cancer, and should be considered for palliative chemotherapy in this group of patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pfister, D. G. et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 22, 330–353 (2004).
Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006).
Pirker, R. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525–1531 (2009).
Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).
[No authors listed]. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J. Natl Cancer Inst. 91, 66–72 (1999).
Frasci, G. et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 18, 2529–2536 (2000).
Gridelli, C. et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J. Natl Cancer Inst. 95, 362–372 (2003).
Quoix, E. et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378, 1079–1088 (2011).
Delbaldo, C. et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292, 470–484 (2004).
D'Addario, G. et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J. Clin. Oncol. 23, 2926–2936 (2005).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
R Pirker declares he is a consultant and he receives honoraria from Eli Lilly, Merck Serono, Pierre Fabre and Roche.
Rights and permissions
About this article
Cite this article
Pirker, R. Advanced NSCLC—should we use doublets in elderly patients?. Nat Rev Clin Oncol 8, 694–696 (2011). https://doi.org/10.1038/nrclinonc.2011.147
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.147
